Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R2 | O00459 | 11/20 | 0.47 |
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236197 | 0.88 | ROCK1 (0.38) | PIK3R2RORCCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4240984 | 0.85 | NCF1 (0.43) | RORCCYP3A4CYP2C9HTR3A | |
| Hydrochloric Acid SCHEMBL4239416 | 0.84 | NCF1 (0.43) | RORCCYP3A4CYP2C9HTR3A | |
| SCHEMBL4247704 | 0.84 | HTR3A (0.38) | NR4A2HTR3A | |
| Hydrochloric Acid SCHEMBL4236769 | 0.83 | HTR3A (0.38) | NR4A2CYP1A2CYP2C19HTR3A | |
| Trifluoroacetic Acid SCHEMBL4247336 | 0.83 | L3MBTL1 (0.42) | PIK3R2RORCCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4241610 | 0.82 | ROCK1 (0.39) | RORCNR4A2HTR3A | |
| SCHEMBL4244642 | 0.82 | NTSR1 (0.43) | — | |
| SCHEMBL4239922 | 0.82 | PABPC1 (0.40) | PIK3R2RORC | |
| SCHEMBL4244196 | 0.81 | KDM4E (0.44) | CYP3A4CYP1A2CYP2C19HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| US-7638521-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214820-A1 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | PIK3R2 2322/4885RORC 464/4885CYP3A4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.